Ikena Oncology Inc. (IKNA): Forward P/S Multiple

Corporate company logo of Ikena Oncology (IKNA)

Ikena Oncology, Inc. (IKNA) brings together leading scientists dedicated to the deep pursuit of targeted therapy methods. Despite the search for a buyer and the suspension of its primary project, solid balance sheet liquidity ensures stability. The forward price-to-sales ratio on this chart reflects sentiment dynamics, with the metric settling at 104.50. Business efficiency is increasing through AI automation and robotic design of new drug formulas.

IKNA Ikena Oncology: Market Cap to Projected Revenue in the range 07/04/2022 - 03/07/2025

Comprehensive metric breakdowns and analytics for Ikena Oncology Inc. (IKNA)

Initial company analysis:IKNA (Ikena Oncology Inc.)
Manufactured products of Ikena Oncology

Ikena Oncology, Inc. (IKNA) focuses on metabolic cancer therapy, where future monopoly patent rights determine the business value. By analyzing the projected P/S multiple, an investor can see the ratio of current market capitalization to expected revenue, which allows for an assessment of the degree of market optimism regarding drug commercialization and helps determine a fair entry threshold for the asset over a long-term horizon.

Competitor analysis for Ikena Oncology, Inc.

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aura Biosciences Inc (AURA)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc.)|SLS: Forward P/S Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tuhurabio.com HURA|Forward P/S Multiple TARA|FATE: Future Price to Revenue|Forward P/S Multiple WHWK (Aadi Bioscience)|TCRX (TScan) - Future Price to Revenue|Champions Oncology, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio XBiotech Inc XBIT|CVM: Forward P/S Multiple|OSTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Forward P/S Multiple artivabio.com|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Limited)|Veru - Market Cap to Projected Revenue|Tempest Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio xiliotx.com (XLO)|Renovaro - Forward P/S Multiple|Mural Oncology (MURA) - Forward Price-to-Revenue Multiple|KAPA: Forward P/S Multiple|OKUR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CytoMed Therapeutics Limited|CRIS: Forward Price to Sales|Forward P/S Multiple APLM|Forward P/S Multiple tharimmune.com (THAR)|Advanced Biomed Corp - Forward Price-to-Revenue Multiple|Forward Price to Sales GNPX|Calidi Biotherapeutics, Inc. - Forward P/S Multiple|Sunshine Biopharma (SBFM) - Forward Price-to-Revenue Multiple|XBIO: Forward P/S Multiple|SLRX - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PPBT|Forward P/S Multiple American Oncology Network|Price-to-Projected Revenue Ratio BeOne Medicines (BGNE)|CKPT: Future Price to Revenue|Forward P/S Multiple ELEV (Elevation Oncology Inc.)|Forward P/S Multiple iCAD Corp ICAD|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple